December 11, 2018 11:03 AM EST

Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

ENDPOINTS

→ Amgen has handed a “modest” tech transfer fee over to Entera $ENTX to get them started on a discovery pact focused on inflammatory diseases …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

ENDPOINTS

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Am­gen en­lists En­tera in a drug dis­cov­ery pact; Boehringer brings out the bud­get ax

ENDPOINTS

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?